StreetInsider.com News Articles

Form 6-K EUPRAXIA PHARMACEUTICALS For: Oct 15

Thu, 15 Oct 2026 10:13:00 -0400

si-local-file:///var/storage/secattach/20261015/27191518.html

Eupraxia hits enrollment target in EoE drug trial, interim data due

Thu, 15 Oct 2026 08:04:18 -0400

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) announced it has reached its enrollment target of 120 patients in the Phase 2b placebo-controlled portion of its RESOLVE trial, which is evaluating EP-104GI for the treatment of eosinophilic esophagitis (EoE).

The company said the 120th patient was enrolled and treated on Oct. 12, 2026. The trial is evaluating doses of 120mg and 160mg of EP-104GI compared to a vehicle control, with patients randomized 1:1:1. Eupraxia noted that patients who have completed screening and qualification may still be dosed, potentially bringing the final number above 120.

An internal data management team has conducted periodic reviews of unblinded

Eupraxia hits enrollment target in EoE drug trial, interim data due

Thu, 15 Oct 2026 08:04:18 -0400

An internal data management team has conducted periodic reviews of unblinded

Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis

Thu, 15 Oct 2026 08:00:00 -0400

Eupraxia reached its target enrollment of 120 patients in the Phase 2b placebo-controlled blinded portion of the RESOLVE trial
The Company has a statistical team who are doing periodic reviews of the unblinded data to ensure that the statistical assumptions and sample size on efficacy are adequate and do not need to be revised. These reviews have confirmed that the sample size as designed does not need to be adjusted
Within both parts of the RESOLVE trial (open-label Phase 1b/2a and placebo-controlled Phase 2b), over 3,000 injections of EP-104GI or vehicle have been administered with no treatment-related Serious Adverse Events

Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis

Thu, 15 Oct 2026 08:00:00 -0400

Eupraxia reached its target enrollment of 120 patients in the Phase 2b placebo-controlled blinded portion of the RESOLVE trial
The Company has a statistical team who are doing periodic reviews of the unblinded data to ensure that the statistical assumptions and sample size on efficacy are adequate and do not need to be revised. These reviews have confirmed that the sample size as designed does not need to be adjusted
Within both parts of the RESOLVE trial (open-label Phase 1b/2a and placebo-controlled Phase 2b), over 3,000 injections of EP-104GI or vehicle have been administered with no treatment-related Serious Adverse Events

Form 6-K EUPRAXIA PHARMACEUTICALS For: Oct 09

Fri, 09 Oct 2026 08:27:00 -0400
si-local-file:///var/storage/secattach/20261009/27169472.html

Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences

Fri, 09 Oct 2026 08:00:00 -0400

VANCOUVER, British Columbia, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today is pleased to announce that three abstracts related to Company’s ongoing Phase 1b/2 RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis ("EoE") have been accepted and will be presented at: (i) the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting & Postgraduate Course, being held October 9-14, 2026 in Nashville, Tennessee, and (ii)

Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences

Fri, 09 Oct 2026 08:00:00 -0400

VANCOUVER, British Columbia, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today is pleased to announce that three abstracts related to Company’s ongoing Phase 1b/2 RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis ("EoE") have been accepted and will be presented at: (i) the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting & Postgraduate Course, being held October 9-14, 2026 in Nashville, Tennessee, and (ii)

Eupraxia Pharmaceuticals (EPRX) Reiterated at Overweight by Cantor Fitzgerald - 'Stock Remains Undervalued'

Thu, 08 Oct 2026 07:06:11 -0400

Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $19.00 price target on Eupraxia Pharmaceuticals (NASDAQ: EPRX).
The analyst commented, "Eupraxia went from being an under the radar stock earlier this year to quickly climbing at the top of our inbound list... We built two simulation valuation models, including the conservative base case (assumes 500,000 U.S. patients with EoE) and the bull case (assumes 1,000,000 U.S. patients by later this decade). For simplicity, we looked only at the U.S. market, which means all other regions (i.e., EU) and indications that Eupraxia may evaluate (GI strictures, Fibrostenosing Crohn’s, etc.) represent potential

H.C. Wainwright Reiterates Buy Rating on Eupraxia Pharmaceuticals (EPRX)

Thu, 01 Oct 2026 07:05:26 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $11.00 price target on Eupraxia Pharmaceuticals (NASDAQ: EPRX).
The analyst commented: "We reiterate our Buy rating and $11 price target on Eupraxia following the 52-week EP-104GI update, which we view as a positive and more meaningful for the commercial thesis than for clinical de-risking. Cohort 9, the highest 160 mg dose also being evaluated in randomized Phase 2b, maintained SDI-defined clinical remission in 66% (2/3) of patients through Week 52 after a single administration, with mean SDI improvement of 3.0 points at both Weeks 36 and 52. Across Cohorts 5–9, 64%

Form 6-K EUPRAXIA PHARMACEUTICALS For: Sep 30

Wed, 30 Sep 2026 08:05:00 -0400
si-local-file:///var/storage/secattach/20260930/27125642.html

Eupraxia reports 52-week EP-104GI data in esophageal disease trial

Wed, 30 Sep 2026 08:00:14 -0400

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, TSX: EPRX) released updated clinical data from its Phase 1b/2a RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis, a condition marked by inflammation of the esophagus.

According to data from the press release, 64% of patients, or 9 of 14, across cohorts 5 through 9 remained in clinical remission at 52 weeks following a single administration of EP-104GI. Clinical remission was defined as a reduction of at least three points from baseline on the Straumann Dysphagia Index.

In the highest dose group, Cohort 9, which received 20 injections of 8 mg each, two of three

Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

Wed, 30 Sep 2026 08:00:00 -0400

The highest dose group of EP-104GI (Cohort 9) demonstrated durability of symptom responses out to 52 weeks, with 66% of patients (2 of 3) maintaining clinical remission¹
The second highest dose group of EP-104GI (Cohort 8b) continued to show meaningful histologic reduction in inflammation and fibrosis with Stage –0.26 and Grade –0.27 in EoEHSS at 36 weeks
The Cohort 8b and Cohort 9 responses are consistent with clinical and histologic responses seen across all cohorts analyzed to date; in total, 9 of 14 patients (64%) have remained in clinical remission 52 weeks after receiving a single administration of EP-104GI

Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

Wed, 30 Sep 2026 08:00:00 -0400

The highest dose group of EP-104GI (Cohort 9) demonstrated durability of symptom responses out to 52 weeks, with 66% of patients (2 of 3) maintaining clinical remission¹
The second highest dose group of EP-104GI (Cohort 8b) continued to show meaningful histologic reduction in inflammation and fibrosis with Stage –0.26 and Grade –0.27 in EoEHSS at 36 weeks
The Cohort 8b and Cohort 9 responses are consistent with clinical and histologic responses seen across all cohorts analyzed to date; in total, 9 of 14 patients (64%) have remained in clinical remission 52 weeks after receiving a single administration of EP-104GI

Wedbush Starts Eupraxia Pharmaceuticals (EPRX) at Outperform

Thu, 24 Sep 2026 06:50:17 -0400
(Updated - September 24, 2026 6:50 AM EDT)
Wedbush analyst Martin Fan initiates coverage on Eupraxia Pharmaceuticals (NASDAQ: EPRX) with a Outperform rating and a price target of $17.00.
The analyst comments "Initiating EPRX at OUTPERFORM, $17 PT: We see EoE (eosinophilic esophagitis) as the next major investor opportunity in GI, with EPRX likely positioning ahead of biologics and presenting favorable risk/reward on an upcoming Q4 readout. EPRX is a clinical-stage biopharmaceutical company developing an injected polymerencapsulated therapeutic, EP-104, for GI and rheumatologic indications. Prior clinical results in EoE show durable efficacy with results lasting one year, suggesting long-term redosing potential in

Wedbush Starts Eupraxia Pharmaceuticals (EPRX) at Outperform

Thu, 24 Sep 2026 06:50:17 -0400
(Updated - September 24, 2026 6:50 AM EDT)
Wedbush analyst Martin Fan initiates coverage on Eupraxia Pharmaceuticals (NASDAQ: EPRX) with a Outperform rating and a price target of $17.00.
The analyst comments "Initiating EPRX at OUTPERFORM, $17 PT: We see EoE (eosinophilic esophagitis) as the next major investor opportunity in GI, with EPRX likely positioning ahead of biologics and presenting favorable risk/reward on an upcoming Q4 readout. EPRX is a clinical-stage biopharmaceutical company developing an injected polymerencapsulated therapeutic, EP-104, for GI and rheumatologic indications. Prior clinical results in EoE show durable efficacy with results lasting one year, suggesting long-term redosing potential in

Stifel Reiterates Buy Rating on Eupraxia Pharmaceuticals (EPRX)

Thu, 24 Sep 2026 05:23:47 -0400

Stifel analyst Samimy Annabel reiterated a Buy rating and $25.00 price target on Eupraxia Pharmaceuticals (NASDAQ: EPRX).
The analyst comments "We reiterate our Buy on EPRX, $25 TP. As EPRX is approaching the Ph.2b RESOLVE interim analysis of EP-104GI (locally-administered fluticasone) in EoE, we had management on the road where they outlined expectations into this release, its significance for the final dataset and its relevance in context of currently available treatments. The Ph.1/2a open-label study continues to provide incremental clues regarding the target product profile/TPP, with demonstration of durability up to 9 months and more than a handful patients out to

Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences

Tue, 08 Sep 2026 08:00:00 -0400

VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (Nasdaq: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced today that its common shares have commenced trading on the Nasdaq Global Select Market. The Company also announced that members of its management team will participate in upcoming investor conferences.

The Company’s common shares were previously listed on the Nasdaq Capital Market and will continue to trade under the ticker symbol “EPRX.”

Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences

Tue, 08 Sep 2026 08:00:00 -0400

VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (Nasdaq: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced today that its common shares have commenced trading on the Nasdaq Global Select Market. The Company also announced that members of its management team will participate in upcoming investor conferences.

The Company’s common shares were previously listed on the Nasdaq Capital Market and will continue to trade under the ticker symbol “EPRX.”

Form EFFECT EUPRAXIA PHARMACEUTICALS

Tue, 25 Aug 2026 06:04:00 -0400
si-local-file:///var/storage/secattach/20260825/26970336.html

Form EFFECT EUPRAXIA PHARMACEUTICALS

Tue, 25 Aug 2026 06:04:00 -0400
si-local-file:///var/storage/secattach/20260825/26970336.html

Form F-10/A EUPRAXIA PHARMACEUTICALS

Wed, 19 Aug 2026 15:35:00 -0400
si-local-file:///var/storage/secattach/20260819/26949791.html

Form F-10/A EUPRAXIA PHARMACEUTICALS

Wed, 19 Aug 2026 15:35:00 -0400
si-local-file:///var/storage/secattach/20260819/26949791.html

Form SCHEDULE 13G/A EUPRAXIA PHARMACEUTICALS Filed by: MANCHESTER MANAGEMENT CO LLC

Thu, 13 Aug 2026 13:03:00 -0400
si-local-file:///var/storage/secattach/20260813/26919414.html

Form SCHEDULE 13G/A EUPRAXIA PHARMACEUTICALS Filed by: MANCHESTER MANAGEMENT CO LLC

Thu, 13 Aug 2026 13:03:00 -0400
si-local-file:///var/storage/secattach/20260813/26919414.html